Introduction {#s1}
============

*Candida* species are the most common opportunistic fungal pathogens in debilitated or immunecompromised hosts with high rates of mortality (up to 40%) (Hajjeh et al., [@B16]; Wisplinghoff et al., [@B30]; Kullberg and Arendrup, [@B19]; Pappas et al., [@B21]). Although the majority of cases of invasive candidiasis (IC) are attributed to *Candida albicans*, globally, there are increasing rates of infection by non-*C. albicans* species (Kullberg and Arendrup, [@B19]; Xiao et al., [@B31]; Pappas et al., [@B21]). The prevalence of *Candida glabrata* infections, in particular, has increased in the last decade, and this species is now the second most common cause of candidemia in the USA, accounting for up to one-third of cases of fungemia (Pfaller et al., [@B23]; Guinea, [@B15]). Data from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study have indicated that *C. glabrata* species complex was the third most common non-*C. albicans* species in China (Wang et al., [@B28]; Xiao et al., [@B31]).

*Candida glabrata* complex comprises *C. glabrata* sensu stricto but also encompasses the cryptic species *Candida bracarensis* and *Candida nivariensis* (Hou et al., [@B17]). Yet within *C. glarbata* sensus strcito *per se*, intra-species delineation is useful, not only for molecular epidemiological studies but for investigation of biological niches and determining the route of infection transmission. Several molecular typing methods, e.g., pulse field gel electrophoresis (PFGE), multilocus sequence typing (MLST) assays and microsatellite analysis have been established to determine genetic relatedness of *C. glabrata* (Dodgson et al., [@B10]; Foulet et al., [@B13]; Lin et al., [@B20]; Brisse et al., [@B6]; Enache-Angoulvant et al., [@B11]; Abbes et al., [@B2]). Of these, MLST is a highly discriminatory tool that can be standardized to allow objective comparison of results between centers. The use of a set of six gene fragments of *C. glabrata (FKS, LEU2, NMT1, TRP1, UGP1*, and *URA3*) is recommended (<http://cglabrata.mlst.net/>) (Dodgson et al., [@B10]). Microsatellite marker analysis is another rapid, reliable technique with several multilocus microsatellite systems proposed (Foulet et al., [@B13]; Brisse et al., [@B6]; Enache-Angoulvant et al., [@B11]; Abbes et al., [@B2]).

Data on the susceptibilities to antifungal agents are also important to guide best practice empirical antifungal therapy in patients with suspected *C. glabrata* IC (Yapar, [@B32]). *C. glabrata* is known to exhibit reduced susceptibility or resistance to fluconazole and the other azoles (Pfaller et al., [@B24]; Delliere et al., [@B8]). Further, resistance to the echinocandins (up to 10% in some centers), as well as of echinocandin and azole co-resistance is of growing concern in the USA (Pfaller et al., [@B22]; Alexander et al., [@B4]; Pham et al., [@B25]). In Europe, the prevalence of echinocandin resistance amongst *C. glabrata* isolates is low (\<3%) (Delliere et al., [@B8]). In China, data on azole and echinocandin resistance are relatively sparse (Xiao et al., [@B31]).

In the present study, we investigated the nationwide molecular epidemiology and *in vitro* antifungal susceptibility of *C. glabrata* sensu stricto isolates causing IC in China during 2010--2014. In this study, MLST genotyping as well microsatellite analysis techniques were employed given their high discriminatory utility.

Materials and methods {#s2}
=====================

Ethics statement
----------------

The study was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (No. S-263). Written informed consent were obtained from all patients in the study for permission to study the isolates cultured from them for scientific research.

Yeast isolates and identification
---------------------------------

*Candida glabrata* isolates were collected prospectively over the 5-year study period from patients enrolled in the CHIF-NET study, a laboratory-based, national multicenter surveillance program conducted during August 2009 to July 2014. Only unique isolates i.e., only one strain per patient, were studied (Wang et al., [@B28]). A total of 411 clinical isolates from 411 patients in 11 hospitals (eight provinces) across China were analyzed (Figure [1](#F1){ref-type="fig"}, see Acknowledgments for participating hospitals). Isolates were identified as *C. glabrata* by a previously-established algorithm incorporating matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Vitek MS, bioMérieux, Marcy l\'Etoile, France) supplemented with rDNA internal transcribed spacer (ITS) sequencing (Zhang et al., [@B33]). Only *C. glabrata* sensu stricto isolates were studied and the confidence value of Vitek MS was ≥90%. For each isolate, a minimum of five colonies were picked from a pure culture together and stored at −80°C in separate vials until use. Early experiments showed that the MLST and microsatellite results were identical for each of these five colonies (data not shown) and previous study described mixture of genotype in one out of 101 (1/101, 1%) isolates (Delliere et al., [@B8]).

![**Geographic distribution of the 11 study centers involved in this study and number of isolates collected in each center (shown in brackets)**. Hospital codes: BD, Peking University First Hospital; GZ, The First Affiliated Hospital of Sun Yat-Sen University; H1, The First Affiliated Hospital of Harbin Medical University; H4, the Fourth Affiliated Hospital of Harbin Medical University; HX, West China Hospital; LR, The People\'s Hospital of Liaoning Province; PU, Peking Union Medical College Hospital; RJ, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University; TJ, Tongji Hospital; TZ, Tianjin Medical University General Hospital; Z1, The First Hospital of China Medical University.](fmicb-08-00880-g0001){#F1}

Multilocus sequence typing (MLST)
---------------------------------

Total DNA was extracted from pure cultures as described previously (Wang et al., [@B28]). Briefly, six housekeeping gene loci (*FKS, LEU2, NMT1, TRP1, UGP1*, and *URA3*) were studied (Dodgson et al., [@B10]). The PCR products were sequenced in both directions using the DNA analyzer ABI 3730XL system (Applied Biosystems, Foster City, CA). Nucleotide sequences were analyzed manually to ensure high quality sequences, and then queried against the *C. glabrata* MLST database (<http://cglabrata.mlst.net>) to assign alleles for each locus. The sequence type (ST) was then defined according to isolates\' allelic profiles. Novel allele types in each novel ST were confirmed twice by sequencing in both directions.

Microsatellite analysis
-----------------------

Yeast isolates were genotyped using six highly polymorphic microsatellite markers namely *RPM2, ERG3, MTI, GLM4, GLM5*, and *GLM6*, chosen for their high discriminatory power (Abbes et al., [@B2]). The forward primers were labeled with carboxyfluorescein (FAM), hexachlorofluorescein (HEX), faststart universal SYBR Green Master (ROX), and carbosytetramethylrhodamine (TAMRA). Amplification reactions were performed as previously reported (Abbes et al., [@B2]). Following PCR, amplicons were sized by capillary electrophoresis on an ABI 3730XL DNA Analyzer (Applied Biosystems,) coupled with GeneMarker v1.8 software (SoftGenetics LLC, State College, PA, USA). Allele sizes were scored with respect to the GeneScan™ 500 LIZ® Size Standard (Applied Biosystems).

Antifungal susceptibility tests
-------------------------------

Susceptibility tests were performed by using the Sensititre YeastOne™ YO10 (SYO) methodology (Thermo Scientific, Cleveland, OH, USA). *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258 were quality control strains. MIC values were interpreted according to CLSI M27-S4 guidelines for fluconazole and echinocandins (Clinical and Laboratory Standards Institute, [@B27]). The breakpoint for resistance to fluconazole is MIC \> 32 μg/ml, to anidulafungin and caspofungin is MIC ≥ 0.5 μg/ml and to micafungin is MIC ≥ 0.25 μg/ml (Clinical and Laboratory Standards Institute, [@B27]). Where there were no clinical break points (for voriconazole, itraconazole, posaconazole, 5-flucytosine and amphotericin B), species-specific epidemiological cut-off values (ECVs) were used to define isolates as wide-type (WT) or non-WT. The ECV for non-WT to voriconazole and 5-flucytosine is MIC \> 0.5 μg/ml and to itraconazole, posaconazole and amphotericin B is MIC \> 2 μg/ml (Huang et al., [@B18]).

Statistical analysis
--------------------

The genetic relationships of the isolates were determined by cluster analysis using the minimum-spanning tree available in the BioNumerics software v 6.5 (Applied Maths). To compare the discriminatory power of different molecular methods, we used an index of discrimination (D) based on Simpson\'s index of diversity and confidence intervals for D were determined by a method described previously by Grundmann et al. ([@B14]).

Data were analyzed with IBM SPSS software (version 22.0; IBM SPSS Inc., New York, USA). Categorical variables were compared using the χ^2^ test. A *P* value of 0.05 was considered significant.

Results {#s3}
=======

Source of isolates, demographics and body site of isolation
-----------------------------------------------------------

Of 411 isolates, 163 (39.7%) were from patients admitted in the Intensive care unit (ICU), 29.7% (122/411) from patients in the Surgery Department, 18.2% (75/411) from the Medical Department, 4.9% (20/411) from the Emergency Department and 7.5% (31/411) from other departments. The average age of the patients (241 males and 170 females) was 60 ± 18.4 years (range 0-96). Nearly one-half (200/411; 48.7%) of the isolates were obtained from blood cultures, 23.1% (95/411) were from ascitic fluid (Tables [S1](#SM5){ref-type="supplementary-material"}, [S2](#SM6){ref-type="supplementary-material"}), 5.1% (21/411) from pus and 4.6% (19/411) from venous catheter. The remaining isolates (*N* = 76) were obtained from bile, pleural fluid and other sterile body fluids.

MLST and microsatellite analysis
--------------------------------

In general, MLST analysis revealed a low degree of genetic diversity within *C. glabrata* although the six-locus based MLST scheme showed a large number of STs overall---it allowed for the differentiation of 35 sequence types (STs) among 411 isolates, including 24 novel STs (PU 1-PU 24). The commonest ST, however, was ST7 (273/411 or 66.4% of isolates), where this ST was the predominant ST across all 11 hospitals, followed by ST3 (*n* = 39; 9.5%) (Figure [2A](#F2){ref-type="fig"}). The diversity index varied from 0.33 for *UGP1* to 0.53 for *NMT1/TRP1*. The D value from all 6 markers was 0.55 (95% confidence interval: 0.49--0.61; Table [1](#T1){ref-type="table"}).

![**Minimum spanning tree analysis based on allelic profiles of multilocus sequence typing (MLST) and microsatellites genotypes**. The different circle colors represent different hospitals. In **(A)**, each circle corresponds to a MLST ST. For **(B)**, each circle corresponds to a microsatellite genotype.](fmicb-08-00880-g0002){#F2}

###### 

**Discriminatory power of the typing methods used in this study**.

  **Methods/Marker**   **No. of genotypes/Different allels**   **Index of discrimination**
  -------------------- --------------------------------------- -----------------------------
  **MLST**             **35**                                  **0.55**
      FKS              9                                       0.5
      LEU2             9                                       0.47
      NMT1             14                                      0.53
      TRP1             16                                      0.53
      UGP1             7                                       0.33
      URA3             11                                      0.49
  **Microsatellite**   **79**                                  **0.88**
      RPM2             4                                       0.46
      MTI              8                                       0.61
      ERG3             14                                      0.52
      GLM4             13                                      0.71
      GLM5             14                                      0.7
      GLM6             10                                      0.53

*MLST, multilocus sequence typing*.

On analysis of ST according to body site of isolation, the majority of isolates from blood (136/200, 68%) and ascitic fluid (60/95, 63.2%), but also all from other specimen types were also of the ST7 type (*n* = 273, 66.4%) followed by ST3 (*n* = 39, 9.5%) (Table [S1](#SM5){ref-type="supplementary-material"}). Both these STs were identified in 10 of the 11 hospitals (Figure [2A](#F2){ref-type="fig"}) and further, were the predominant ST in all of fluconazole susceptible-dose dependent (S-DD; *n* = 343) and fluconazole-resistant isolates (*n* = 68) (Figures [S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}). A further 10 STs, each encompassing two to 14 isolates, were also detected, whereas the remaining 23 STs comprised one isolate each (Table [S1](#SM5){ref-type="supplementary-material"}).

Using microsatellite analyses, there were 79 genotypes amongst the 411 isolates designated as genotypes T01 to T79 (Table [2](#T2){ref-type="table"}, Figures [2B](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). Of the 79 genotypes, T25 (*n* = 125, 30.4%) and T31 (*n* = 51, 12.4%) were the most prevalent followed by genotype T41 (*n* = 29, 7.1%). T25 and T31 were the predominant genotypes in fluconazole susceptible-dose dependent (S-DD) as well as fluconazole-resistant isolates. Overall genotype distribution was similar for all clinical samples (Figures [S3](#SM3){ref-type="supplementary-material"}, [S4](#SM4){ref-type="supplementary-material"}). Twenty-four genotypes each comprised 2--25 isolates, with the remaining 52 genotypes comprising one isolate each. The diversity index varied from 0.46 for *RPM2* to 0.71 for *GLM4*. We found a D value of 0.88 (95% confidence interval: 0.86--0.90) by combining the six microsatellites (Table [1](#T1){ref-type="table"}). Notably, there were 28 different microsatellite genotypes within ST7 (Figure [3](#F3){ref-type="fig"}), illustrating the higher D value of microsatellite-based polymorphism typing over MLST. The ST of *C. glabrata* was congruent (or consistent) with their microsatellite genotyping.

###### 

**Designations of the 79 genotypes**.

  **Genotype**   **Designation of microsatellite markers**   **No. (%) of isolates**                           
  -------------- ------------------------------------------- ------------------------- ----- ----- ----- ----- ------------
  T01            122                                         181                       229   287   274   325   1 (0.2)
  T02            122                                         181                       237   287   274   325   1 (0.2)
  T03            122                                         181                       242   281   265   322   5 (1.2)
  T04            122                                         181                       242   284   265   322   1 (0.2)
  T05            122                                         181                       243   284   265   322   1 (0.2)
  T06            122                                         234                       243   266   262   247   1 (0.2)
  T07            122                                         234                       243   266   262   289   9 (2.2)
  T08            122                                         234                       243   266   265   289   2 (0.5)
  T09            122                                         234                       244   266   262   289   2 (0.5)
  T10            122                                         234                       244   266   265   289   1 (0.2)
  T11            122                                         235                       244   266   262   289   5 (1.2)
  T12            122                                         238                       242   293   262   310   7 (1.7)
  T13            122                                         238                       242   302   262   310   2 (0.5)
  T14            122                                         238                       242   305   262   310   1 (0.2)
  T15            122                                         238                       242   308   262   310   1 (0.2)
  T16            122                                         238                       243   293   262   310   1 (0.2)
  T17            122                                         238                       243   305   262   310   1 (0.2)
  T18            128                                         181                       229   278   268   325   1 (0.2)
  T19            128                                         181                       229   284   268   325   2 (0.5)
  T20            128                                         181                       243   287   262   307   1 (0.2)
  T21            128                                         181                       250   278   268   322   1 (0.2)
  T22            128                                         197                       241   272   298   295   1 (0.2)
  T23            128                                         197                       241   275   277   295   1 (0.2)
  T24            128                                         197                       241   275   295   295   11 (2.7)
  T25            128                                         197                       241   275   298   295   125 (30.4)
  T26            128                                         197                       241   275   301   295   2 (0.5)
  T27            128                                         197                       241   275   301   298   1 (0.2)
  T28            128                                         197                       241   275   304   295   6 (1.5)
  T29            128                                         197                       241   275   328   295   1 (0.2)
  T30            128                                         197                       241   275   331   295   1 (0.2)
  T31            128                                         197                       241   278   298   295   51 (12.4)
  T32            128                                         197                       241   278   298   301   1 (0.2)
  T33            128                                         197                       241   278   298   310   1 (0.2)
  T34            128                                         197                       241   278   301   295   2 (0.5)
  T35            128                                         197                       241   278   301   298   1 (0.2)
  T36            128                                         197                       241   278   304   295   1 (0.2)
  T37            128                                         197                       241   278   304   298   2 (0.5)
  T38            128                                         197                       241   278   304   301   7 (1.7)
  T39            128                                         197                       241   281   298   295   2 (0.5)
  T40            128                                         197                       242   278   298   295   22 (5.4)
  T41            128                                         197                       242   278   301   295   29 (7.1)
  T42            128                                         197                       242   278   304   307   1 (0.2)
  T43            128                                         197                       242   278   322   295   1 (0.2)
  T44            128                                         197                       242   278   331   295   1 (0.2)
  T45            128                                         198                       241   272   298   295   1 (0.2)
  T46            128                                         198                       241   275   295   295   1 (0.2)
  T47            128                                         198                       241   275   298   295   1 (0.2)
  T48            128                                         198                       241   275   304   295   1 (0.2)
  T49            128                                         198                       241   278   304   298   1 (0.2)
  T50            128                                         198                       242   275   301   295   1 (0.2)
  T51            128                                         200                       242   275   322   295   1 (0.2)
  T52            128                                         213                       229   287   268   325   1 (0.2)
  T53            128                                         258                       242   278   262   325   6 (1.5)
  T54            128                                         262                       242   278   259   325   1 (0.2)
  T55            128                                         262                       242   278   259   325   1 (0.2)
  T56            128                                         262                       243   278   265   325   1 (0.2)
  T57            128                                         262                       243   281   259   325   2 (0.2)
  T58            134                                         181                       229   275   268   325   1 (0.2)
  T59            134                                         181                       229   278   268   325   3 (0.2)
  T60            134                                         181                       229   281   268   325   1 (0.2)
  T61            134                                         204                       237   269   280   301   1 (0.2)
  T62            134                                         204                       243   269   262   310   1 (0.2)
  T63            134                                         204                       243   269   262   325   25 (6.1)
  T64            134                                         204                       244   269   262   325   13 (3.2)
  T65            134                                         213                       229   287   268   325   1 (0.2)
  T66            134                                         213                       241   281   265   298   3 (0.7)
  T67            134                                         213                       242   281   265   298   1 (0.2)
  T68            134                                         213                       242   284   265   298   1 (0.2)
  T69            134                                         213                       243   269   268   325   1 (0.2)
  T70            134                                         235                       241   284   268   325   1 (0.2)
  T71            134                                         238                       261   269   265   292   1 (0.2)
  T72            140                                         197                       241   275   265   295   6 (1.5)
  T73            140                                         197                       241   278   265   295   2 (0.5)
  T74            140                                         197                       242   278   265   295   1 (0.2)
  T75            140                                         228                       242   278   265   298   7 (1.7)
  T76            140                                         228                       243   281   265   298   1 (0.2)
  T77            140                                         228                       243   299   265   298   1 (0.2)
  T78            140                                         230                       242   278   265   298   1 (0.2)
  T79            140                                         267                       243   281   265   298   1 (0.2)

*The table shows the 79 genotypes (T01--T79) among 411 nonrepetitive Candida glabrata sensu stricto isolates generated by microsatellite genotyping*.

![**Minimum spanning tree analysis based on allelic profiles of multilocus sequence typing (MLST)**. Each circle corresponds to a MLST ST. Different circle colors represent microsatellites genotypes.](fmicb-08-00880-g0003){#F3}

Antifungal susceptibilities
---------------------------

The susceptibilities to antifungal drugs are shown in Table [3](#T3){ref-type="table"}. Sixty-eight of 411 (16.5%) *C. glabrata* isolate*s* were resistant to fluconazole (MICs \>32 μg/mL) (Clinical and Laboratory Standards Institute, [@B27]) with 40/200 (20%) of bloodstream isoaltes being resistant. The non-WT rates of *C. glabrata* for voriconazole, itraconazole and posaconazole were 28.7, 6.8, and 7.3% of isolates, respectively. Notably, 14.8% (61/411) of *C. glabrata* isolates were cross-resistant/non-WT to fluconazole and voriconazole. Caspofungin, micafungin and anidulafungin exhibited \>99% susceptibility rates against all isolates. All isolates had WT MICs to amphotericin B. Only 0.2% (1/411) of *C. glabrata* isolates were non-WT to 5-flucytosine. The resistance rate for fluconazole increased significantly from 5.3% in 2013 to 31.4% in 2014 (P \< 0.01) and non-WT rate for voriconazole increased significantly from 21.1% in 2013 to 82.6% in 2014 (*P* \< 0.05). While the non-WT rate for itraconazole and posaconazole both decreased from 8.4% in 2012 to 1.3% in 2013 (*P* \< 0.05) and remains 3.5% in 2014. There were no significant trends for resistance rate or non-WT rate for echinocandins, amphotericin B and 5-flucytosine (all the *P* \> 0.05).

###### 

**Antifungal susceptibilities for ***Candida glabrata*** species collected in this study**.

  **Parameter**   **Fluconazole**   **Voriconazole**   **Itraconazole**   **Posaconazole**   **Anidulafungin**   **Micafungin**   **Caspofungin**   **5-flucytosine**   **Amphotericin B**
  --------------- ----------------- ------------------ ------------------ ------------------ ------------------- ---------------- ----------------- ------------------- --------------------
  Range           1--\>256          0.03--\>8          0.12--\>16         0.25--\>8          ≤0.015--\>8         ≤0.008--\>8      ≤0.008--\>8       ≤0.06--\>64         ≤0.12--2
  MIC~90~         64                2                  1                  2                  0.06                0.015            0.12              0.06                1
  MIC~50~         16                0.25               0.5                1                  0.03                0.015            0.06              0.06                0.5
  0.78            19.29             0.36                                  1.20               0.028               0.013            0.073             0.062               0.65
  R/non-WT (%)    16.5              28.7               6.8                7.3                0.5                 0.5              0.5               0.2                 0

*GM, geometric mean; R, resistant; non-WT, non-wide-type*.

Discussion {#s4}
==========

*Candida glabrata* is an increasingly important pathogen in the United States and Europe but also in China (Pfaller et al., [@B23]; Wang et al., [@B28]; Guinea, [@B15]; Xiao et al., [@B31]; Delliere et al., [@B8]). Knowledge of both the diversity of molecular types, as well as antifungal susceptibility profiles of *C. glabrata* are important for understanding the epidemiology of this organism. Our study, for the first time, provides a description of the genetic diversity and antifungal susceptibility of a large number of *C. glabrata* strains. Major findings of the study included the observations that fluconazole resistant rates increased 3-fold over the 5-year period, the frequency of isolates with non-WT MICs to voriconazole rose 7-fold, and that Chinese *C. glabrata* sensu stricto isolates exhibit relatively low intraspecies genetic diversity.

Despite the position of *C. glabrata* as a pathogen in China, we noted that the isolation rate of *C. glabrata* slightly decreased in 2013 from 2010. The reason for this apparent drop may be because of a large-scale outbreak of *Candida parapsilosis* sensu stricto fungemia involving \>100 isolates in one of the 11 participating hospitals during the study period (Wang et al., [@B29]). Nonetheless *C. glabrata* accounted for 10.2% (200/1963) of candidemia cases in the present study, similar to that found in Finland (9.0%) and Norway (13.2%) (Guinea, [@B15]) but substantially less than that in Denmark (25%) and the USA (21%) (Pfaller et al., [@B23]; Arendrup et al., [@B5]). In this study, most of isolates were recovered from blood (200/411; 48.7%), while in a French study, most of isolates were collected from respiratory sample (81/268; 30.2%) (Delliere et al., [@B8]).

Strain typing is essential for epidemiological investigation and a variety of molecular methods have been applied for genotyping of *C. glabrata*. PFGE exhibits high discriminatory power, but is limited by the high initial investment costs and slow turn-around times (Abbes et al., [@B1]). MLST has the advantage of providing unambiguous results, which allows different laboratories to easily compare data and allows for the construction of international internet-accessible databases (Dodgson et al., [@B10]). However, the D value was only 0.55 in the present study. It has been reported that MLST system developed for *C. glabrata* appears to be less discriminatory than that for *C. albicans*. One plausible explanatio*n* is that *C. albicans* is a diploid organism, as opposed to the haploid status of *C. glabrata*, which allows for greater potential for detecting the presence of genetic heterogeneity with the former (Dodgson et al., [@B10]). As such, we found a low degree of genetic diversity amongst *C. glabrata* using MLST analysis. The majority (75.9%) of isolates comprised only two STs, ST7 and ST3. *C. glabrata* ST3 and ST5 types have been predominant in Europe, while ST7 and ST30 types are reported to be the most common in Japan (Dodgson et al., [@B10]), and ST8 and ST18 types in the USA (Dodgson et al., [@B10]). The differences in STs according to geography, highlight the significance of acquiring local data.

The results of the present study show that in comparison to MLST, the *D*-value for microsatellite typing was 0.88, higher than MLST employed herein, but lower than that in one study using microsatellite analysis (Abbes et al., [@B2]). Nonetheless, the results of microsatellite genotyping in our study were concordant with those of a predominant genotype identified. Our isolates were collected only from Chinese patients and it is logical that coevolution of genetic markers will provide similar results by any chose typing method. The *D*-value may be improved by incorporation of a greater number of more loci by the microsatellite analysis approach and this is the focus of ongoing study (Dodgson et al., [@B10]; Foulet et al., [@B13]; Abbes et al., [@B2]; Delliere et al., [@B8]). This approach is also simple to use and is inexpensive (US\$9 per sample analyzed vs. US\$24 for MLST).

Of note, there was no correlation between genetic type and isolates from patients at the different hospitals or from departments by either MLST or microsatellite typing. We also found no association between genetic type and susceptibility to fluconazole (Tables [S1](#SM5){ref-type="supplementary-material"}, [S2](#SM6){ref-type="supplementary-material"}, Figures [S1](#SM1){ref-type="supplementary-material"}, [S3](#SM3){ref-type="supplementary-material"}). However, our results do not exclude the possibility that certain STs or microsatellite genotypes may have the capacity to acquire resistance through drug exposure at differing frequencies. Many studies have likewise found no association between *C. glabrata* genotypes and antifungal resistance (Dodgson et al., [@B10]; Abbes et al., [@B3]). However, Dhieb et al. noted that both microsatellite genotypes and MALDI-TOF MS analysis could highlight *C. glabrata* population structures associated with specific geographic origin or antifungal drug resistance pattern (Dhieb et al., [@B9]). In our study, we noticed that during 2010--2011 in one hospital (Hospital BD) 80.8% (21/26) *C. glabrata* isolates were of the same genetic type (ST7 and T25), suggesting possible clonal presence/transmission of *C. glabrata*. 14 isolates were from blood, four from ascitic fluid, two from venous catheter and one from bronchoalveolar lavage fluid, and five of these isolates (5/21, 23.8%) were collected from patients in the same department and were resistant to fluconazole. Further study is needed to investigate the clinical events at this hospital stemming from this observation.

Importantly, our results show that only 6.8% of *C. glabrata* isolates were non-WT/resistant to all four azoles tested in contrast to results noted in the USA (Pfaller et al., [@B24]), but comparable to those reported by Wang et al. ([@B28]) and Delliere et al. ([@B8]). Of note, however, the proportion of isolates that were fluconazole--resistant and/or had non-WT MICs to voriconazole rose significantly over 5 years. That many of these isolates remained susceptible to posaconazole and itraconazole underscores the importance of susceptibility testing for individual isolates.

Echinocandins have become the first-line treatment of IC caused by *C. glabrata* (Pfaller et al., [@B22]). In this context, the fact that only two isolates (0.5% of all isolates) tested resistant to the echinocandins (Clinical and Laboratory Standards Institute, [@B27]) is reassuring. One *C. glabrata* isolate was observed to have an MIC \> 8 μg/mL to all three echinocandins. The low rate of echinocandin resistance here contrasts with that in the USA and elsewhere where resistance has bene reported in up to 10% and with one-third of those isolates being multidrug resistant (Pfaller et al., [@B22]; Alexander et al., [@B4]; Eschenauer et al., [@B12]; Pham et al., [@B25]). However, one French study observed only a low proportion of isolates to be resistant to micafungin (0.7%) using the Etest (bioMérieux, Marcy l\'Etoile, France) and employing European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, with only 1/268 isolates showing cross-resistance to both antifungal classes (Delliere et al., [@B8]). Importantly, one echinocandin-resistant isolate in the present study was also resistant to fluconazole, which MICs for fluconazole, voriconazole, itraconazole and posaconazole were 128, 8, ≥16, and ≥8 μg/mL, respectively and 0.5 μg/mL for echinocandins. This is the first multi-drug resistant isolate reported in China. Elsewhere, about 11.1% of fluconazole-resistant *C. glabrata* were co-resistant to one or more echinocandins study (Pfaller et al., [@B22]).

One study limitation is that we used the SYO methodology to perform antifungal susceptibility testing. The essential agreement between this methodology and the CLSI as well as with the EUCAST reference procedures are known to be very high (Cuenca-Estrella and Rodriguez-Tudela, [@B7]; Posteraro and Sanguinetti, [@B26]). In addition, the Sensititre method is a simple and affordable alternative to these reference methodologies and is widely used in clinical mycology laboratories (Posteraro and Sanguinetti, [@B26]).

Conclusion {#s5}
==========

This is the first systemic study regarding the molecular epidemiology and antifungal susceptibility profiles of *C. glabrata* isolates in China. Identification of relatedness between *C. glabrata* is important in understanding their molecular epidemiology. Our results suggest that some *C. glabrata* populations are more prominent than others. Further investigations are needed to confirm this hypothesis.
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**Minimum spanning tree analysis based on allelic profiles of multilocus sequence typing (MLST)**. Different circle colors represent fluconazole susceptible-dose dependent (S-DD) (green) or resistant (MIC \> 32 μg/ML) (red). Each circle in corresponds to a MLST ST.
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**Minimum spanning tree analysis based on allelic profiles of multilocus sequence typing (MLST)**. Different circle colors represent sample types. Each circle in corresponds to a MLST ST.
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**Minimum spanning tree analysis based on allelic profiles of microsatellites genotypes**. Different circle colors represent fluconazole susceptible-dose dependent (S-DD) (green) or resistant (MIC \> 32 μg/ML) (red). Each circle in corresponds to a microsatellites genotype.
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**Minimum spanning tree analysis based on allelic profiles of microsatellites genotypes**. Different circle colors represent sample types. Each circle in corresponds to a microsatellites genotype.
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**Distribution of ***Candida glabrata*** isolates of different sequence types (STs) in different specimen types and prevalence of fluconazole resistant (MIC \> 32 μg/mL) isolates**.
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**Distribution of ***Candida glabrata*** isolates of different microsatellite genotypes in different specimen types and prevalence of fluconazole resistant (MIC \> 32 μg/mL) isolates**.
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